Skip to main content
Delfa

← All trials/NCT03774095

UnknownPhase NA

Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance

Effects of Pine Nut and Olive Oil as FFA1/FFA4 and GPR119 Agonists on Glucose Tolerance in Healthy Overweight or Obese Subjects

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Estimated enrollment

10

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 27.5-40

Primary endpoints

•Glucose•Insulin•C-peptide

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03774095
Org study IDPINO 5

Timeline

Milestones

Study start2018-06-11actual
Study first posted2018-12-12actual
Last update posted2018-12-14actual
Primary completion2018-12-30estimated
Study completion2018-12-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age40 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

body mass index (BMI) of 27.5-40 kg/m2, normal glucose tolerance (two hours OGTT plasma glucose ≤ 7.8 mmol/l), normal blood pressure and normal screening blood samples (kidney and liver function, lipids and hematology) and written informed consent -

Exclusion criteria

any chronic disease including past gastrointestinal diseases or gastrointestinal surgery, first degree relatives with diabetes, food allergies of relevance, need for prescriptive medicine, smoking, body weight changes (> 3 kg within three month prior), intake of dietary supplements (<1 month prior) or any type of restrictive diet for example calorie restriction, vegan diet etc.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Glycemic / diabetes
3
Safety / tolerability / PK
1

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

Glucose

Time frame:6 hours

descriptive

Primary/protocol endpoint

Insulin

Time frame:6 hours

descriptive

Primary/protocol endpoint

C-peptide

Time frame:6 hours

descriptive

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Gastrointestinal tolerability

Time frame:24 hours

descriptive

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

GLP-1

Time frame:6 hours

descriptive

Primary/protocol endpoint/low confidence

GIP

Time frame:6 hours

descriptive

Primary/protocol endpoint/low confidence

Ghrelin

Time frame:6 hours

descriptive

Primary/protocol endpoint/low confidence

Appetite

Time frame:6 hours

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.